Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

Table 1 Patient characteristics, clinical status, and therapies

Patient Number	Study Drug^a	HIV-1 Status	Age (years)	Baseline Weight (kg)	No. Lung Fields Involved^b	Medication^c
Thailand
1	t	+	43	48.0	6	Rifater, E
2	t	+	51	49.0	4	Rifater, E
3	t	−	32	43.0	4	Rifater, E
4	t	−	65	40.5	4	Rifater, E
5	t	−	46	43.3	4	Rifater, E
6	t	+	60	41.3	4	RPE
7	t	−	31	52.8	1	RIP
8	t	+	38	48.3	2	Rifater, E
9	t	−	25	56.5	3	Rifater, E
10	t	+	25	49.5	1	Rifater, E
11	t	+	49	44.5	3	Rifater, E
12	t	−	38	50.5	2	Rifater, E
13	P	−	25	40.0	2	Rifater, E
14	P	−	53	50.0	4	Rifater, E
15	t	−	55	52.0	5	Rifater, E
16	P	−	64	49.0	5	Rifater, E
17	t	−	22	42.0	1	Rifater, E
18	P	−	46	63.3	1	Rifater, E
19	t	−	63	71.0	3	Rifater, E
20	P	−	42	58.0	NA	Rifater, E
New York
21	t	+	44	63.3	1	RIPE + Anti retroviral
22	t	+	37	71.0	2	RIPE + Anti retroviral
23	P	+	33	77.7	1	RIPE + Anti retroviral
24	P	+	45	76.5	3	RIPE + Anti retroviral
25	t;t;p;t	−	32	53.7	3	RIPE
26	t;t	+	35	66.5	2	RIPE + Anti retroviral
27	t;t	+	30	63.3	3	RIPE + Anti retroviral
28	t;t;p;t	−	38	74.5	3	RIPE + CIP¶+ ETH¶
29	p;t;t	+	42	83.8	1	RIPE + Anti retroviral
30	t;p;t;p	−	46	89.6	2	RIPE

NA, not available; R, Rifampin; I, Isoniazid; P, Pyrazinamide; E, Ethambutol; CIP¶, Cipro for 16 days; ETH¶, Ethionamide for 16 days.
^aPatients received either thalidomide (t), placebo (p), or multiple cycles of t or p in the sequence shown.
^bInfiltration, granulomas, or cavities present on chest X-ray: a total of six lung fields were evaluated and results given for each patient.
^cRlifater, Rifampin isoniazid pyrazinamide.

ISSN: 1528-3658